search
Back to results

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

Primary Purpose

Moderate to Severe Plaque Psoriasis

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TLL018 tablets
Sponsored by
Hangzhou Highlightll Pharmaceutical Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Moderate to Severe Plaque Psoriasis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have had a diagnosis of moderate to severe plaque psoriasis for at least 6 months prior to Baseline;
  • Subjects with moderate to severe plaque psoriasis covering ≥10% BSA, with a PASI ≥12 and sPGA score ≥3 at Baseline;
  • Able and willing to give written informed consent.

Exclusion Criteria:

  • Other types of psoriasis (such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, etc.);
  • Current drug-induced psoriasis, e.g., a new onset of psoriasis or an exacerbation of psoriasis induced by beta blockers, calcium channel blockers, antimalarial drugs or lithium;
  • History or symptoms of malignancy in any organ system regardless of treatment, and regardless of evidence of recurrence or metastasis;
  • Any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject's participation in the study.

Sites / Locations

  • 88 Jiefang Road, Shangcheng District, Hangzhou City, Zhejiang Province

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Cohort 1

Cohort 2

Cohort 3

Cohort 4

Arm Description

TLL018 tablets, 1piece,BID

TLL018 tablets, 2pieces, BID

TLL018 tablets, 3pieces, BID

TLL018 placeboes, 3pieces, BID

Outcomes

Primary Outcome Measures

treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
adverse events (AEs) according to severity
Number of adverse events (AEs) according to severity
blood pressure from baseline
Change of blood pressure from baseline
pulse rate from baseline
Change of pulse rate from baseline
respiratory rate from baseline
Change of respiratory rate from baseline
temperature from baseline
Change of oral temperature from baseline
clinical laboratory abnormalities compared to baseline
Number of participants with clinical laboratory abnormalities compared to baseline
ECG parameters from baseline
Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline
physical examination findings from baseline
Number of participants with changes in physical examination findings from baseline
Cmax of TLL018
Maximum observed plasma concentration (Cmax) of TLL018

Secondary Outcome Measures

PASI score decreased from baseline at week 4
The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 4 when comparing TLL-018 with placebo
PASI score decreased from baseline at week 8
The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 8 when comparing TLL-018 with placebo
PASI score decreased from baseline at week 12
The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 12 when comparing TLL-018 with placebo
(sPGA) 0/1 response at week 4
static Physician Global Assessment (sPGA) 0/1 response
(sPGA) 0/1 response at week 8
static Physician Global Assessment (sPGA) 0/1 response
(sPGA) 0/1 response at week 12
static Physician Global Assessment (sPGA) 0/1 response

Full Information

First Posted
April 7, 2022
Last Updated
September 20, 2023
Sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05342428
Brief Title
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
Official Title
A Phase Ⅰb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of TLL-018 in Subjects With Moderate to Severe Plaque Psoriasis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
June 10, 2022 (Actual)
Primary Completion Date
August 30, 2023 (Actual)
Study Completion Date
August 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
Detailed Description
Successfully screened subjects will be randomized in a ratio of 2:2:2:1 and stratified to previous biologics use for psoriasis. After a 4-week screening period (day -28-0), subjects will be randomly assigned to treatment for 12 weeks. Clinical psoriasis area and severity index (PASI), Physician's Global Assessment (PGA), dermatological Quality of Life Index (DLQI), physical exams and Laboratory tests will be performed at baseline, the end of weeks 4, 8 and 12 respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Moderate to Severe Plaque Psoriasis

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
73 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
TLL018 tablets, 1piece,BID
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
TLL018 tablets, 2pieces, BID
Arm Title
Cohort 3
Arm Type
Experimental
Arm Description
TLL018 tablets, 3pieces, BID
Arm Title
Cohort 4
Arm Type
Placebo Comparator
Arm Description
TLL018 placeboes, 3pieces, BID
Intervention Type
Drug
Intervention Name(s)
TLL018 tablets
Other Intervention Name(s)
TLL018 Placeboes
Intervention Description
Oral tablets administered at different doses BID daily for 12 weeks.
Primary Outcome Measure Information:
Title
treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Description
Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Time Frame
From day 1 to Weeks 12
Title
adverse events (AEs) according to severity
Description
Number of adverse events (AEs) according to severity
Time Frame
From day 1 to Weeks 12
Title
blood pressure from baseline
Description
Change of blood pressure from baseline
Time Frame
From day 1 to Weeks 12
Title
pulse rate from baseline
Description
Change of pulse rate from baseline
Time Frame
From day 1 to Weeks 12
Title
respiratory rate from baseline
Description
Change of respiratory rate from baseline
Time Frame
From day 1 to Weeks 12
Title
temperature from baseline
Description
Change of oral temperature from baseline
Time Frame
From day 1 to Weeks 12
Title
clinical laboratory abnormalities compared to baseline
Description
Number of participants with clinical laboratory abnormalities compared to baseline
Time Frame
From day 1 to Weeks 12
Title
ECG parameters from baseline
Description
Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline
Time Frame
From day 1 to Weeks 12
Title
physical examination findings from baseline
Description
Number of participants with changes in physical examination findings from baseline
Time Frame
From day 1 to Weeks 12
Title
Cmax of TLL018
Description
Maximum observed plasma concentration (Cmax) of TLL018
Time Frame
0 hour (pre-dose - within 30 minutes prior to dosing), and at 0.5, 1, 2, 4 and 12 hours post-dose
Secondary Outcome Measure Information:
Title
PASI score decreased from baseline at week 4
Description
The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 4 when comparing TLL-018 with placebo
Time Frame
Baseline to Week 4
Title
PASI score decreased from baseline at week 8
Description
The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 8 when comparing TLL-018 with placebo
Time Frame
Baseline to Week 8
Title
PASI score decreased from baseline at week 12
Description
The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 12 when comparing TLL-018 with placebo
Time Frame
Baseline to Week 12
Title
(sPGA) 0/1 response at week 4
Description
static Physician Global Assessment (sPGA) 0/1 response
Time Frame
Baseline to Weeks 4
Title
(sPGA) 0/1 response at week 8
Description
static Physician Global Assessment (sPGA) 0/1 response
Time Frame
Baseline to Weeks 8
Title
(sPGA) 0/1 response at week 12
Description
static Physician Global Assessment (sPGA) 0/1 response
Time Frame
Baseline to Weeks 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have had a diagnosis of moderate to severe plaque psoriasis for at least 6 months prior to Baseline; Subjects with moderate to severe plaque psoriasis covering ≥10% BSA, with a PASI ≥12 and sPGA score ≥3 at Baseline; Able and willing to give written informed consent. Exclusion Criteria: Other types of psoriasis (such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, etc.); Current drug-induced psoriasis, e.g., a new onset of psoriasis or an exacerbation of psoriasis induced by beta blockers, calcium channel blockers, antimalarial drugs or lithium; History or symptoms of malignancy in any organ system regardless of treatment, and regardless of evidence of recurrence or metastasis; Any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject's participation in the study.
Facility Information:
Facility Name
88 Jiefang Road, Shangcheng District, Hangzhou City, Zhejiang Province
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310009
Country
China

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

We'll reach out to this number within 24 hrs